Pre-Open Stock Movers 04/13: (NVCR) (MFNC) (RIGL) Higher; (BALY) (LHDX) (AMRN) Lower (more...)
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Pre-Open Stock Movers:
Novocure (NASDAQ: NVCR) 57.4% HIGHER; today announced an update regarding its phase 3 pivotal LUNAR trial of Tumor Treating Fields (TTFields) in stage 4 non-small cell lung cancer (NSCLC) following platinum failure. Following a routine review of the study by an independent data monitoring committee (DMC), Novocure was informed that the pre-specified interim analysis for the LUNAR trial would be accelerated given the length of accrual and the number of events observed, to date. The interim analysis included data from 210 patients accrued to the LUNAR trial through February 2021. After review of the interim analysis report, the DMC concluded that the LUNAR trial should continue with no evidence of increased systemic toxicity.
Mackinac Financial Corporation (NASDAQ: MFNC) 54.9% HIGHER; Nicolet Bankshares, Inc. (NASDAQ: NCBS) and Mackinac Financial Corporation (NASDAQ: MFNC) today jointly announced the execution of a definitive merger agreement, pursuant to which Nicolet will acquire Mackinac and its wholly-owned banking subsidiary, mBank.
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) 15.5% HIGHER; announced positive topline results from a multi-center, Phase 2 clinical trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized patients with COVID-19.
Zai Lab Limited (NASDAQ: ZLAB) 14.7% HIGHER; Zai Lab and Novocure (NASDAQ: NVCR) today announced an update regarding its phase 3 pivotal LUNAR trial of Tumor Treating Fields (TTFields) in stage 4 non-small cell lung cancer (NSCLC) following platinum failure. Following a routine review of the study by an independent data monitoring committee (DMC), Novocure was informed that the pre-specified interim analysis for the LUNAR trial would be accelerated given the length of accrual and the number of events observed, to date. The interim analysis included data from 210 patients accrued to the LUNAR trial through February 2021. After review of the interim analysis report, the DMC concluded that the LUNAR trial should continue with no evidence of increased systemic toxicity.
vTv Therapeutics Inc. (Nasdaq: VTVT) 12.8% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for TTP399 as an adjunctive therapy to insulin for the treatment of type 1 diabetes. TTP399 is a novel, oral, investigational once-daily glucokinase activator.
B. Riley Financial Inc. (NASDAQ: RILY) 10.6% HIGHER; will replace The Michaels Companies Inc. (NASD:MIK) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, April 15.
Bally's Corporation (NYSE: BALY) 10% LOWER; announced that it has agreed to purchase the Tropicana Las Vegas, Nevada casino from Gaming and Leisure Properties, Inc., a publicly traded gaming focused real estate investment trust . Bally's estimates the transaction to be valued at approximately $308 million.
Lucira Health Inc. (NASDAQ: LHDX) 9.7% LOWER; BofA Securities downgraded from Neutral to Underperform with a price target of $9.00.
Digimarc Corporation (NASDAQ: DMRC) 7% HIGHER; announced the retirement of Bruce Davis as Digimarc's President and Chief Executive Officer and as Chairman and member of Digimarc's Board of Directors, effective immediately. Riley McCormack, a current member and Lead Director of the Digimarc Board, has been appointed as the Company's President and Chief Executive Officer, effective today, and will remain as a director of the Company.
Moderna (NASDAQ: MRNA) 5.6% HIGHER; ticks higher after U.S. calls for a pause in J&J vaccine after clotting cases.
Amarin Corporation plc (NASDAQ: AMRN) 4.1% LOWER; today announced that John F. Thero, 60, has informed the board of directors of his plan to retire as president and chief executive officer, effective August 1, 2021. He will also step down from the board at that time. The board has appointed Karim Mikhail, 50, Amarins senior vice president and head of commercial for Europe, to succeed Mr. Thero as the companys next president and chief executive officer. Mr. Mikhail will join the board upon his effective date. Mr. Thero will continue to provide his guidance and expertise to the company in an advisory capacity through the end of 2021.
NiSource Inc. (NYSE: NI) 3% LOWER; announced today its intention to offer to sell, subject to market and other conditions, 7,500,000 Equity Units, each with a stated amount of $100.
Harmonic (NASDAQ: HLIT) 2% HIGHER; today announced that it has entered into a cooperation agreement with Scopia Capital Management LP.
Essential Properties Realty Trust, Inc. (NYSE: EPRT) 1.5% LOWER; commenced an underwritten public offering of 6,500,000 shares of its common stock. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 975,000 shares of common stock. The Company expects to use the net proceeds from the offering to repay amounts outstanding on its revolving credit facility and for general corporate purposes, including potential future investments. All of the shares are being offered by the Company.
Chewy (NYSE: CHWY) 1.5% LOWER; Holder BC Said to Offer 6.1M Share Block Trade - Bloomberg
Angi Inc. (NASDAQ: ANGI) 0.7% HIGHER; Total Angi Inc. Revenue rise 31% in March.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Canadian National Railway (CNI) Expected to Sweeten Kansas City Southern (KSU) Bid - DJ
- Pre-Open Stock Movers 05/12: (LHDX) (UPST) (EYES) Higher; (ARRY) (CURI) (LMND) Lower (more...)
- Henry Schein (HSIC) Announces $400 Million Increase to Share Repurchase Plan
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesB. Riley, Scopia Capital, Standard & Poor's, Pre-Open Losers, Pre-Open Winners, Definitive Agreement, Pre Market Movers, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!